Onokpite, Emmanuel and Jasper, Abiodun Oyinpreye and Edomwonyi, Philomina Nosa and Minervini, Giuseppe (2022) Comparison of Low-Dose Promethazine and Dexamethasone against Ondansetron Monotherapy Given as Antiemetic Prophylaxis during Myomectomy Under Spinal Anesthesia: A Randomized Clinical Trial. Anesthesiology Research and Practice, 2022. pp. 1-9. ISSN 1687-6962
2094662.pdf - Published Version
Download (551kB)
Abstract
Background. Postoperative nausea and vomiting (PONV) prophylaxis is still inadequate for a significant proportion of women undergoing myomectomy under spinal anesthesia; and it substantially decreases patient’s quality of postoperative recovery. Current protocol and practice favor the use of combination therapy like promethazine/dexamethasone for PONV prophylaxis with minimal side effects and cost advantages in low-resource climes. Methodology. Seventy American Society of Anesthesiologist (ASA) class I or II women aged 21–65 years scheduled for myomectomy were recruited and randomized into group A (promethazine/dexamethasone group) and group B (ondansetron group). Myomectomy was performed on each patient using spinal anesthesia. After induction of spinal anesthesia, patients in group A received intravenous promethazine 12.5 mg and dexamethasone 8 mg while group B received intravenous ondansetron 8 mg. Early (0–3 h) and late (4–24 h) PONV was assessed using the numerical scoring scale. Results. Data analysis was done using SPSS version 20. Postoperatively, there was no significant difference in the incidence of early ansd late PONV ( value >0.05) despite the higher incidents in the ondansetron group. The proportion of patients who required rescue antiemetics was more in the ondansetron group when compared with the promethazine/dexamethasone, with minimal and statistically insignificant side effects in both groups. There was significant patient satisfaction in both groups. Conclusion. The study shows that the combination of low-dose promethazine and dexamethasone is comparable to ondansetron when used as prophylaxis for PONV with cost benefits in low-resource environments.
Item Type: | Article |
---|---|
Subjects: | Universal Eprints > Medical Science |
Depositing User: | Managing Editor |
Date Deposited: | 29 Nov 2022 04:45 |
Last Modified: | 18 Sep 2023 09:43 |
URI: | http://journal.article2publish.com/id/eprint/450 |